Concepedia

Vivek Samnotra

VS

Statistics

Publications

4

Citations

117

H-Index

4

Active since

2007

Affiliations

Dana-Farber Cancer Institute(Current)

GlaxoSmithKline (United States)

Memorial Sloan Kettering Cancer Center

University of Virginia

Harvard University

Vivek Samnotra is an author at Dana-Farber Cancer Institute specializing in medicine, cancer pharmacology, and pharmacology.

Publications per year

2007–2023

4

Publications

4

A phase II trial of gefitinib monotherapy in patients with unresectable adrenocortical carcinoma (ACC)

Vivek Samnotra, Rena Vassilopoulou‐Sellin, Antonio Tito Fojo et al. · Journal of Clinical Oncology · 2007 · 52 citations

, , +9

An open-label phase II study of dostarlimab (TSR-042), bevacizumab (bev), and niraparib combination in patients (pts) with platinum-resistant ovarian cancer (PROC): cohort A of the OPAL trial

Joyce F. Liu, Stéphanie Gaillard, Andrea Wahner Hendrickson et al. · Gynecologic Oncology · 2021 · 29 citations

, , +15

Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032)

Leslie M. Randall, David M. O’Malley, Bradley J. Monk et al. · Gynecologic Oncology · 2023 · 26 citations · Full text

, , +14

MOONSTONE/GOG-3032: Interim analysis of a phase 2 study of niraparib + dostarlimab in patients (pts) with platinum-resistant ovarian cancer (PROC).

Leslie M. Randall, David M. O’Malley, Bradley J. Monk et al. · Journal of Clinical Oncology · 2022 · 10 citations

, , +15

1–4 of 4